

CERTIFICATE OF ANALYSIS No.: 2025-15859

CLIENT

Pharmahemp d.o.o., Cesta v Gorice 8
1000 Ljubljana, Slovenija

SAMPLE *

DROPS MEDMAX 6,5% CBD, 6% CBN, 0,5% CBG, 1%
CBGA, 1% CBDA - mct / olive oil



Sample condition: SUITABLE
Sample ID: 2502016
Sample type: Viscous liquid
Batch No.: * DR06525009A

Work order: 2025-112527
Analysis ID: 2025_007
Method ID: PHL_RPC_16C
Method SOP: MET-LAB-001-08

Sample received: 09/01/2025
Start of analysis: 09/01/2025
End of analysis: 09/01/2025
Analyst: Valentina Malin

* Information provided by the client.

CANNABINOID PROFILE		Concentration [% w/w]	Expanded uncertainty [% w/w]	Graphic presentation of relative cannabinoid concentration
CBDV	- Cannabidiol	1.039	0.052	
CBDA	- Cannabidiolic acid	0.959	0.096	
CBGA	- Cannabigerolic acid	0.97	0.13	
CBG	- Cannabigerol	0.49	0.12	
CBD	- Cannabidiol	6.65	0.33	
THCV	- Tetrahydrocannabivarin	0.227	0.036	
CBN	- Cannabinol	5.92	0.30	
Δ⁹-THC	- Δ-9-Tetrahydrocannabinol	< LOQ	n/a	
Δ⁸-THC	- Δ-8-Tetrahydrocannabinol	< LOQ	n/a	
CBL	- Cannabicyclol	< LOQ	n/a	
CBC	- Cannabichromene	< LOQ	n/a	
Δ⁹-THCA	- Δ-9-Tetrahydrocannabinolic acid	< LOQ	n/a	
CBV	- Cannabivarin	0.0423	0.0093	
CBCA	- Cannabichromenic acid	< LOQ	n/a	
CBT	- Cannabicitran	< LOQ	n/a	
CBE	- Cannabielsoin	0.070	0.020	

Units and abbreviations: % w/w = weight percent, < LOQ = below the limit of quantitation (0.03 % w/w), ND = not detected, n/a = not available.


The results given herein apply only to the sample as received and tested. Expanded Uncertainty was calculated using coverage factor $k = 2$, corresponding to a double standard uncertainty and characterizes the interval value in which it is possible to expect the real value with a probability of 95%. This is stated according to the ISO/IEC Guide 98-3.

Total or partial reproduction of this document is not allowed without the permit from PharmaHemp d.o.o. The document does not substitute any other legal document.

Date issued:

09/01/2025

Approved by:


mag. Valentina Malin
Analytical Laboratory Manager

Authorized by:


dr. Boštjan Jančar
Chief Technology Officer